Consilium Wealth Advisory LLC Buys New Holdings in Stryker Co. (NYSE:SYK)

Consilium Wealth Advisory LLC bought a new stake in Stryker Co. (NYSE:SYK - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,418 shares of the medical technology company's stock, valued at approximately $512,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Vanguard Group Inc. increased its holdings in shares of Stryker by 1.0% during the first quarter. Vanguard Group Inc. now owns 31,459,393 shares of the medical technology company's stock worth $11,258,373,000 after buying an additional 309,592 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Stryker by 10.4% during the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company's stock worth $3,096,078,000 after acquiring an additional 813,311 shares during the period. Clearbridge Investments LLC grew its holdings in Stryker by 2.9% during the 2nd quarter. Clearbridge Investments LLC now owns 2,323,452 shares of the medical technology company's stock valued at $790,554,000 after buying an additional 66,482 shares in the last quarter. TD Asset Management Inc lifted its position in Stryker by 2.9% during the first quarter. TD Asset Management Inc now owns 1,601,380 shares of the medical technology company's stock valued at $573,086,000 after purchasing an additional 44,765 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Stryker by 4.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,209,769 shares of the medical technology company's stock valued at $411,624,000 after purchasing an additional 46,375 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Down 0.2 %

SYK traded down $0.84 during trading on Wednesday, reaching $369.02. The stock had a trading volume of 1,364,590 shares, compared to its average volume of 1,257,470. Stryker Co. has a one year low of $266.93 and a one year high of $376.04. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock's 50 day moving average is $360.91 and its two-hundred day moving average is $345.12. The company has a market capitalization of $140.68 billion, a price-to-earnings ratio of 39.55, a P/E/G ratio of 2.77 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.46 EPS. As a group, analysts expect that Stryker Co. will post 12.06 earnings per share for the current year.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Stryker news, insider Viju Menon sold 600 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares in the company, valued at $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company's stock, valued at $3,685,213.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,068 shares of company stock valued at $3,693,972 over the last three months. 5.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on SYK shares. Barclays upped their target price on shares of Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a research note on Thursday, October 31st. Canaccord Genuity Group lifted their target price on Stryker from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Piper Sandler reissued an "overweight" rating and issued a $420.00 price target (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Citigroup boosted their target price on shares of Stryker from $406.00 to $411.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Finally, Stifel Nicolaus dropped their target price on Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.